Lunai Bioworks (NASDAQ:LNAI) Trading Down 6.3% – Time to Sell?

Lunai Bioworks Inc. (NASDAQ:LNAI)’s share price traded down 6.3% during trading on Tuesday . The company traded as low as $0.6959 and last traded at $0.71. 185,926 shares traded hands during trading, an increase of 14% from the average session volume of 163,261 shares. The stock had previously closed at $0.7575.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on LNAI shares. Wall Street Zen upgraded shares of Lunai Bioworks from a “sell” rating to a “hold” rating in a report on Saturday, January 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lunai Bioworks in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Sell”.

Lunai Bioworks Stock Down 6.3%

The stock has a market cap of $16.64 million, a P/E ratio of -10.14 and a beta of 0.46. The company’s 50-day moving average is $1.00.

Lunai Bioworks (NASDAQ:LNAI) last announced its quarterly earnings data on Friday, November 14th. The company reported $0.13 EPS for the quarter.

Institutional Investors Weigh In On Lunai Bioworks

An institutional investor recently bought a new position in Lunai Bioworks stock. Millennium Management LLC acquired a new position in Lunai Bioworks Inc. (NASDAQ:LNAI) during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 202,629 shares of the company’s stock, valued at approximately $288,000. Millennium Management LLC owned 0.87% of Lunai Bioworks as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 71.41% of the company’s stock.

Lunai Bioworks Company Profile

Enochian Biosciences, Inc, a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company’s lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection.